Evaxion Biotech A/S ADR (EVAX) Stock: A SWOT Analysis

Company’s 36-month beta value is -0.02.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The average trading volume of EVAX on April 03, 2024 was 678.21K shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

EVAX) stock’s latest price update

Evaxion Biotech A/S ADR (NASDAQ: EVAX)’s stock price has gone rise by 20.12 in comparison to its previous close of 3.23, however, the company has experienced a 25.16% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-04-02 that Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup – Chief Executive Officer Birgitte Rono – Chief Scientific Officer Jesper Nissen – Chief Operating Officer and Chief Financial Officer Conference Call Participants Ahu Demir – Ladenburg Thalmann Swayampakula Ramakanth – H.C. Wainwright Thomas Flaten – Lake Street Capital Markets Richard Ramanius – Redeye Christian Kanstrup Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results.

EVAX’s Market Performance

EVAX’s stock has risen by 25.16% in the past week, with a monthly rise of 14.45% and a quarterly drop of -43.42%. The volatility ratio for the week is 11.15% while the volatility levels for the last 30 days are 8.62% for Evaxion Biotech A/S ADR The simple moving average for the past 20 days is 26.80% for EVAX’s stock, with a -51.14% simple moving average for the past 200 days.

Analysts’ Opinion of EVAX

H.C. Wainwright, on the other hand, stated in their research note that they expect to see EVAX reach a price target of $14. The rating they have provided for EVAX stocks is “Buy” according to the report published on February 12th, 2024.

EVAX Trading at -5.20% from the 50-Day Moving Average

After a stumble in the market that brought EVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.03% of loss for the given period.

Volatility was left at 8.62%, however, over the last 30 days, the volatility rate increased by 11.15%, as shares surge +21.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.09% lower at present.

During the last 5 trading sessions, EVAX rose by +25.16%, which changed the moving average for the period of 200-days by -70.15% in comparison to the 20-day moving average, which settled at $3.09. In addition, Evaxion Biotech A/S ADR saw -43.42% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for EVAX

Current profitability levels for the company are sitting at:

  • -302.09 for the present operating margin
  • 1.0 for the gross margin

The net margin for Evaxion Biotech A/S ADR stands at -301.13. The total capital return value is set at -3.83. Equity return is now at value -1239.54, with -126.90 for asset returns.

Based on Evaxion Biotech A/S ADR (EVAX), the company’s capital structure generated 2.11 points at debt to capital in total, while cash flow to debt ratio is standing at 1.95. The debt to equity ratio resting at -1.9. The interest coverage ratio of the stock is -13.17.

Currently, EBITDA for the company is -21.62 million with net debt to EBITDA at -0.24. When we switch over and look at the enterprise to sales, we see a ratio of 271.63. The receivables turnover for the company is 0.07for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.

Conclusion

In a nutshell, Evaxion Biotech A/S ADR (EVAX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts